3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 3
1
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Conditions
Neoplasms
9
Carcinoma, Non-Small-Cell Lung
9
Melanoma
7
Prostatic Neoplasms
5
Ovarian Neoplasms
5
Neoplasm Metastasis
5
Recurrence
4
Carcinoma, Renal Cell
4
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Head and Neck Neoplasms
3
Colorectal Neoplasms
3
Uterine Cervical Neoplasms
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Lung Neoplasms
2
Glioma
2
Fallopian Tube Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Merkel Cell
2
Breast Neoplasms
2
Uterine Neoplasms
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Solid Tumor
1
Skin Neoplasms
1
Sarcoma
1
Mycosis Fungoides
1
Multiple Myeloma
1
Interventions
Sorafenib
26
Nivolumab
21
pembrolizumab
15
Bevacizumab
14
lenvatinib
12
atezolizumab
9
Cyclophosphamide
9
Ipilimumab
8
durvalumab
6
camrelizumab
5
apatinib
5
Specimen Handling
5
Radiosurgery
5
tislelizumab
4
fludarabine
4
Immunotherapy, Adoptive
4
Fluorouracil
4
Doxorubicin
4
tremelimumab
3
toripalimab
3
sintilimab
3
regorafenib
3
cabozantinib
3
X-Rays
3
Magnetic Resonance Spectroscopy
3
Injections
3
Everolimus
3
Ethiodized Oil
3
Erlotinib Hydrochloride
3
tepotinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Carcinoma, Hepatocellular
×
cemiplimab
×
Clear all
NCT06923761
2026-01-28
EMITT-1
Grey Wolf Therapeutics
Phase 1/2
Recruiting
300 enrolled